Latest news
Oppenheimer Adjusts PT on UroGen Pharma to $60 From $50, Maintains Outperform Rating - MoomooMoomoo · Fri, 07 Aug 2026 03:51:49 GMTOppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 - MoomooMoomoo · Fri, 07 Aug 2026 03:12:57 GMTA Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75 - MoomooMoomoo · Thu, 06 Aug 2026 19:36:04 GMTTD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 - MoomooMoomoo · Thu, 06 Aug 2026 07:52:45 GMTUroGen Pharma 2Q Loss $14.4M >URGN - MoomooMoomoo · Wed, 05 Aug 2026 16:22:16 GMTUroGen Pharma Q2 Net Loss Narrows, Revenue Rises - MoomooMoomoo · Wed, 05 Aug 2026 15:18:36 GMTUroGen Pharma 2Q Loss/Shr 28c >URGN - MoomooMoomoo · Wed, 05 Aug 2026 13:31:11 GMTPress Release: UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights - MoomooMoomoo · Wed, 05 Aug 2026 12:00:00 GMT